This exploratory application proposes to develop a quantitative real-time assay to detect residual disease in children with B-cell non-Hodgkin lymphoma (NHL) with the long term goal to be used clinically to assess treatment response or determine if intervention is needed. Although the majority of children diagnosed with B-cell NHL respond well to treatment, up to 30-40% still relapse or do not respond to therapy. One potential mechanism to identify these high-risk cases is to determine if minimal residual disease (MRD) is still present during primary therapy. While it remains to be shown if early intervention in pediatric B-cell NHL cases with residual disease is effective, if we translate the experience from other pediatric malignancies, it is likely that improvements in real-time assessment of residual disease in pediatric B-cell NHL are warranted. Capitalizing on the current experience in the lab with quantitative real-time PCR, (QRT-PCR), the objective of this exploratory application is to design and test the feasibility of a QRT-PCR assay to assess MRD in specimens from children diagnosed with B-cell NHL. The focus of this project will be to design markers from immunoglobulin heavy chain and/or T-cell receptor genes that are aberrant in childhood NHL using QRT-PCR without the need of diagnostic tissue from the original tumor. Our hypothesis is that a QRT-PCR assay is efficient in measuring MRD in clinical specimens from children with B-cell NHL; without diagnostic tissue available. To further expand upon the assay that will be developed, MRD specimens that are identified will be tested for mitochondrial DNA to study a potential mechanism for residual disease from persistent or compensatory increase in mitochondria, a source of energy for the cells. This will incorporate mtDNA assays currently established in the lab. This proposal is innovative by proposing to identify MRD in pediatric B-cell NHL without the need of initial or diagnostic tissue, and at the same time being able to take advantage of ongoing retrospective studies with pediatric B-cell NHL clinical specimens. The significance of the study lies in developing an assay which could potentially impact and improve the prognosis of children diagnosed with B-cell NHL. The assay developed by this exploratory proposal could be incorporated into pediatric B-cell NHL studies to assess MRD on therapy or to assess the efficacy of innovative therapies. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA121955-01
Application #
7123686
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Jessup, John M
Project Start
2006-07-10
Project End
2008-06-30
Budget Start
2006-07-10
Budget End
2007-06-30
Support Year
1
Fiscal Year
2006
Total Cost
$105,184
Indirect Cost
Name
University of Hawaii
Department
Miscellaneous
Type
Schools of Medicine
DUNS #
965088057
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Kusao, Ian K T; Troelstrup, David L; Agsalda, Melissa A et al. (2012) Effective use of small-interfering RNA to characterize residual B-cell non-Hodgkin lymphoma cells following chemotherapy. J Hematol Malig 2:5-12
Shiramizu, Bruce; Goldman, Stanton; Kusao, Ian et al. (2011) Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report. Br J Haematol 153:758-63
Egan, Kathryn; Kusao, Ian; Troelstrup, David et al. (2010) Mitochondrial DNA in residual leukemia cells in cerebrospinal fluid in children with acute lymphoblastic leukemia. J Clin Med Res 2:225-9
Agsalda, Melissa; Kusao, Ian; Troelstrup, David et al. (2009) Screening for residual disease in pediatric burkitt lymphoma using consensus primer pools. Adv Hematol 2009:412163
Kusao, Ian; Troelstrup, David; Shiramizu, Bruce (2008) Possible Mitochondria-Associated Enzymatic Role in Non-Hodgkin Lymphoma Residual Disease. Cancer Growth Metastasis 1:3-8
Kusao, Ian; Agsalda, Melissa; Troelstrup, David et al. (2008) Chemotoxicity recovery of mitochondria in non-Hodgkin lymphoma resulting in minimal residual disease. Pediatr Blood Cancer 51:193-7